FDA grants Fast Track Designation to Cellceutix's brilacidin-OM for oral mucositis
Cellceutix announced the FDA has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company's novel defensin-mimetic Brilacidin, for prevention of oral mucositis. There are no FDA approved drugs for the prevention of oral mucositis. November 25, 2015